These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 26954019)

  • 1. Drug Repositioning for Cancer Therapy Based on Large-Scale Drug-Induced Transcriptional Signatures.
    Lee H; Kang S; Kim W
    PLoS One; 2016; 11(3):e0150460. PubMed ID: 26954019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accurate Drug Repositioning through Non-tissue-Specific Core Signatures from Cancer Transcriptomes.
    Xu C; Ai D; Shi D; Suo S; Chen X; Yan Y; Cao Y; Zhang R; Sun N; Chen W; McDermott J; Zhang S; Zeng Y; Han JJ
    Cell Rep; 2018 Oct; 25(2):523-535.e5. PubMed ID: 30304690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrating LINCS Data to Evaluate Cancer Transcriptome Modifying Potential of Small-molecule Compounds for Drug Repositioning.
    Zhao Y; Liu Y; Bai H
    Comb Chem High Throughput Screen; 2021; 24(9):1340-1350. PubMed ID: 33109034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome.
    Raynal NJ; Da Costa EM; Lee JT; Gharibyan V; Ahmed S; Zhang H; Sato T; Malouf GG; Issa JJ
    Mol Cancer Ther; 2017 Feb; 16(2):397-407. PubMed ID: 27980103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of synergistic anti-cancer drug combinations based on drug target network and drug induced gene expression profiles.
    Li X; Xu Y; Cui H; Huang T; Wang D; Lian B; Li W; Qin G; Chen L; Xie L
    Artif Intell Med; 2017 Nov; 83():35-43. PubMed ID: 28583437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conservation of immune gene signatures in solid tumors and prognostic implications.
    Chifman J; Pullikuth A; Chou JW; Bedognetti D; Miller LD
    BMC Cancer; 2016 Nov; 16(1):911. PubMed ID: 27871313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Signature reversion of three disease-associated gene signatures prioritizes cancer drug repurposing candidates.
    Fisher JL; Wilk EJ; Oza VH; Gary SE; Howton TC; Flanary VL; Clark AD; Hjelmeland AB; Lasseigne BN
    FEBS Open Bio; 2024 May; 14(5):803-830. PubMed ID: 38531616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational Drug Repositioning for Gastric Cancer using Reversal Gene Expression Profiles.
    Kim IW; Jang H; Kim JH; Kim MG; Kim S; Oh JM
    Sci Rep; 2019 Feb; 9(1):2660. PubMed ID: 30804389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diverse gene expression patterns in response to anticancer drugs between human and mouse cell lines revealed by a comparative transcriptomic analysis.
    Guo Y; Liang Z; Hou X; Zhang Z
    Mol Med Rep; 2017 Oct; 16(4):4469-4474. PubMed ID: 28791417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An in silico screen links gene expression signatures to drug response in glioblastoma stem cells.
    Riddick G; Song H; Holbeck SL; Kopp W; Walling J; Ahn S; Zhang W; Fine HA
    Pharmacogenomics J; 2015 Aug; 15(4):347-53. PubMed ID: 25446780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset.
    Seashore-Ludlow B; Rees MG; Cheah JH; Cokol M; Price EV; Coletti ME; Jones V; Bodycombe NE; Soule CK; Gould J; Alexander B; Li A; Montgomery P; Wawer MJ; Kuru N; Kotz JD; Hon CS; Munoz B; Liefeld T; Dančík V; Bittker JA; Palmer M; Bradner JE; Shamji AF; Clemons PA; Schreiber SL
    Cancer Discov; 2015 Nov; 5(11):1210-23. PubMed ID: 26482930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DeSigN: connecting gene expression with therapeutics for drug repurposing and development.
    Lee BK; Tiong KH; Chang JK; Liew CS; Abdul Rahman ZA; Tan AC; Khang TF; Cheong SC
    BMC Genomics; 2017 Jan; 18(Suppl 1):934. PubMed ID: 28198666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug and disease signature integration identifies synergistic combinations in glioblastoma.
    Stathias V; Jermakowicz AM; Maloof ME; Forlin M; Walters W; Suter RK; Durante MA; Williams SL; Harbour JW; Volmar CH; Lyons NJ; Wahlestedt C; Graham RM; Ivan ME; Komotar RJ; Sarkaria JN; Subramanian A; Golub TR; Schürer SC; Ayad NG
    Nat Commun; 2018 Dec; 9(1):5315. PubMed ID: 30552330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying Gene Signatures for Cancer Drug Repositioning Based on Sample Clustering.
    Wang F; Ding Y; Lei X; Liao B; Wu FX
    IEEE/ACM Trans Comput Biol Bioinform; 2022; 19(2):953-965. PubMed ID: 32845842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression Profiles of the Individual Genes Corresponding to the Genes Generated by Cytotoxicity Experiments with Bortezomib in Multiple Myeloma.
    Ghasemi M; Alpsoy S; Türk S; Malkan ÜY; Atakan Ş; Haznedaroğlu İC; Güneş G; Gündüz M; Yılmaz B; Etgül S; Aydın S; Aslan T; Sayınalp N; Aksu S; Demiroğlu H; Özcebe OI; Büyükaşık Y; Göker H
    Turk J Haematol; 2016 Dec; 33(4):286-292. PubMed ID: 27095044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved anticancer drug response prediction in cell lines using matrix factorization with similarity regularization.
    Wang L; Li X; Zhang L; Gao Q
    BMC Cancer; 2017 Aug; 17(1):513. PubMed ID: 28768489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.
    Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K
    Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statistically controlled identification of differentially expressed genes in one-to-one cell line comparisons of the CMAP database for drug repositioning.
    He J; Yan H; Cai H; Li X; Guan Q; Zheng W; Chen R; Liu H; Song K; Guo Z; Wang X
    J Transl Med; 2017 Sep; 15(1):198. PubMed ID: 28962576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New drug candidates for treatment of atypical meningiomas: An integrated approach using gene expression signatures for drug repurposing.
    Zador Z; King AT; Geifman N
    PLoS One; 2018; 13(3):e0194701. PubMed ID: 29558515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel drug candidate for the treatment of several soft‑tissue sarcoma histologic subtypes: A computational method using survival‑associated gene signatures for drug repurposing.
    Yang X; Huang WT; Wu HY; He RQ; Ma J; Liu AG; Chen G
    Oncol Rep; 2019 Apr; 41(4):2241-2253. PubMed ID: 30816547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.